Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …

Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with
haematologic malignancies. The paper provides an analysis of the course of breakthrough …

Background: Prior to the introduction of COVID-19 vaccines, SARS-CoV-2 infection in
individuals with haematologic malignancies was associated with a high risk for severe …

Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …

In most cases, the COVID-19 is characterized by mild clinical course, however, there are
groups of patients at high risk of mortality and morbidity of COVID-19, including the older …

SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic.
At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but …

Background: Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus
constitute an important preventive option against COVID-19, especially in fragile patients …

Objective. Patients diagnosed with hematologic malignancies are at increased risk for
severe SARS-CoV-2 infection. We evaluated the serological IgG response following two …

Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with
Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic | Blood | American …